🔗 Share this article

Given that the US undertakes unprecedented changes to its vaccination guidelines, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by questioning COVID-19 shots during the pandemic and has zeroed in on alleged deaths after COVID-19 vaccination in her brief position at the FDA.

Planned Overhauls to Childhood Vaccine Schedule

Public health authorities had intended to announce radical changes to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US out of step with much of the world with no evidence for benefit. This reveal has been pushed back until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A New Direction at the FDA

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon rolling back long-standing vaccines at the FDA.

The new acting director has frequently advocated for halting specific childhood shot schedules in the US to become more like the Danish model, a nation with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on immunizations – usually the domain of Prasad, director of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Qualifications

The appointee has no obvious experience in medication creation, regulation or administrative roles, which has been standard for past leaders of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in running a major agency. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “grasp legal statutes and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that former directors who led the center have had.”

CDER has an enormous range of responsibilities at the FDA, she emphasized.

“Many people just zeroes in on the new drug program, but the off-patent medication office clears numerous generic drugs. There’s a biologic copycat branch, over-the-counter program and other areas, and each of these need to be supervised,” Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative aspect to the role, which supervises over 5,000 employees. “It’s a enormous management job, if you do it right,” the former official added.

Official Statement and Controversial Programs

Regarding concerns about Dr. Høeg's credentials and whether this assignment indicates more teamwork among agency officials on vaccines, a representative responded that the “concerns rely on incorrect assumptions”.

“Her experience aligns with the duties of her role,” the spokesperson stated, citing the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a contentious expedited medication authorization process that reportedly troubled her predecessors. “How are these therapies being picked for this voucher program? Who is making the calls?” Howard questioned. “There is a lot of confidentiality happening at the agency right now.”

Overall, he said, “the Food and Drug Administration seems to be moving towards more relaxed oversight of all drugs, with the exception of shots.”

Established Past Work on Vaccines

Regarding vaccines, Høeg has a more documented, if problematic, track record, Howard observe. She authored a research paper using unverified volunteer-provided data to assess the frequency of myocarditis following COVID-19 vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Among her “policy goals” for the incoming federal leadership featured changing rules for new vaccines and discontinuing “optional” immunizations, she remarked post-election on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of excluding adolescent males from receiving COVID-19 vaccinations.

“She is an all-around ideologue who starts off with her conclusions and works backwards to retrofit the science in a highly deceptive, untruthful way,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|